frost & sullivan cancer therapies analyst briefing
TRANSCRIPT
Cancer Therapies: Getting Targeted and More Personalized
Sangeetha Prabakar, Industry Analyst
Technical Insights, Healthcare
9th September 2008
2
Scope of the Analyst Briefing
� An overview of cancer therapies
� Emerging trends in cancer therapies
� Overview of the factors influencing the future of cancer therapies
� Key opportunities for cancer research
� Drivers, restraints and challenges affecting cancer therapies
� Technology road map
� Noteworthy technologies and products
3
Areas of Major Advances
Nanotechnology
4
Diagnostics
Companion Diagnostics
�Prognosis
�Real Time Screening
�Drug Toxicity
�Drug Response Monitoring
�Prediction of Recurrence
�Pharmacogenomic Studies
Microarrays
5
Therapeutics
Targeted Therapy
�Monoclonal Antibodies
�Enzyme Inhibitors
�Proteasome Inhibitors
�Angiogenesis Inhibitors
6
Drug Delivery
Targeted Delivery
�Liposomes
�Nanoparticles
�Nanodrug Implants
�Polymer Drug Conjugates
7
One drug for a single phenotype
One drug for a specific
population
Personalized care – Patient specific drug
cocktails
Personalized care – one pill for individual
patient.
Future Paradigm of Cancer Care
Molecular DiagnosticsMicroarrays
Targeted TherapiesNanotechnology
Drug Delivery Technologies
Low HighMedium
8
Future Economic Trends in Cancer Care
Molecular Profiling
Molecular Phenotype
Tumor Genotype
Tumor Subtype
Disease Stage
Personalized Medicine
9
Growth Drivers for Cancer Drugs
10
Inadequate Data on Cancer Subtypes
Inadequate Data on Cancer Subtypes
Side Effects of Chemotherapy
Side Effects of Chemotherapy
Complicated Nature of
Chemotherapy
Complicated Nature of
Chemotherapy
Inherent Features of
Cancer Cells Complicate Drug Targeting
Inherent Features of
Cancer Cells Complicate Drug Targeting
Poor Target Specificity/Poor Drug
Solubility
Poor Target Specificity/Poor Drug
Solubility
Multiple Drug ResistanceMultiple Drug Resistance
Insurance/High Costs/Tough Regulatory
Environment
Insurance/High Costs/Tough Regulatory
Environment
Expiring Patent/Generic Threat
Expiring Patent/Generic Threat
Need for Regionalization of Clinical Trials
Need for Regionalization of Clinical Trials
Growth Restraining Factors for Anticancer Drugs
Growth Restraining Factors for Anticancer Drugs
11
Emerging Cancer Research Opportunities
12
Key Players and Their Innovations
13
Your Feedback is Important to Us
Growth Forecasts?
Competitive Structure?
Emerging Trends?
Strategic Recommendations?
Other?
Please inform us by taking our survey.
What would you like to see from Frost & Sullivan?
14
For Additional Information
• To leave a comment, ask the analyst a question, or receive the
free audio segment that accompanies this presentation, please contact Stephanie Ochoa, Social Media Manager at (210) 247-
2421, via email, [email protected], or on Twitter at
http://twitter.com/stephanieochoa.